Analyst moves put Amgen in focus
Amgen (AMGN) is back on investors’ radar after Argus lifted its price target to $460 from $375 while keeping a Buy rating, following second quarter results and drug portfolio updates.
See our latest analysis for Amgen.
At a share price of US$433.73, Amgen has delivered a 30 day share price return of 18.49% and a 1 year total shareholder return of 51.76%, which points to strong recent momentum following its second quarter update and portfolio news.
If Amgen’s recent move has you looking beyond a single stock, this could be a moment to scan for other healthcare companies shaping the future of medicine through 40 healthcare AI stocks
Amgen’s sharp re-rating after its second quarter update and portfolio news could signal a reassessment of the business rather than a passing mood swing. How does that move stack up against what you are actually paying for today?
Most Popular Narrative: 20.5% Overvalued
Compared with Amgen’s last close of $433.73, the most followed narrative on Simply Wall St pins fair value around $360, which creates a clear valuation gap according to that framework.
Here is the cold, data-driven reality.
1. CNPV solves regulatory speed, not the manufacturing bottleneck. Amgen lacks the massive, domestic GLP-1 supply chain infrastructure that Lilly and Novo command. Fast-tracked approval without scale-up capacity only accelerates market-share caps.
Want to see how this narrative still lands on a premium valuation for Amgen? The core of the model rests on a specific revenue glide path, a firm profit margin step up and a future earnings multiple that pushes the share price well above today’s level. Curious which exact assumptions make that fair value number hold together.
Result: Fair Value of $359.98 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, if MariTide execution surprises on capacity or legacy products such as Prolia and Enbrel prove more durable, this bearish Amgen narrative could quickly look overstated.
Find out about the key risks to this Amgen narrative.
Another view on Amgen’s valuation
That user narrative flags Amgen as about 20.5% overvalued around $360 per share. Our DCF model points in the opposite direction, with an estimated future cash flow value of $691.35, which implies Amgen could be trading at a discount. Which set of assumptions do you find more persuasive as an investor?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Amgen for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this mix of optimism and caution around Amgen feels familiar, now is the time to examine the details and decide where you stand. To weigh both sides in one place, start with the 4 key rewards and 1 important warning sign
Looking for more investment ideas beyond Amgen?
If Amgen has you thinking more broadly about your portfolio, do not stop at one opportunity. Cast a wider net now so you do not miss what comes next.
- Target resilient potential by reviewing companies with strong finances through the solid balance sheet and fundamentals stocks screener (50 results).
- Hunt for potential value by scanning opportunities that combine quality with attractive pricing in the 50 high quality undervalued stocks.
- Strengthen your income stream by checking companies with higher yields and robust profiles through the 12 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com